Research Interests
My research interest involve the supportive care of patients with brain tumors. I am particularly interested in the quality of life in patients with brain tumors by improving fatigue, protecting cognition, and improving physical function. Additionally, I serve at the principal investigator for treatment trials for primary brain tumors with a particular interest in low grade glioma, IDH mutant tumors, and primary CNS lymphoma. I am the Director of Supportive Care at the Preston Robert Tisch Brain Tumor Center at Duke.
Selected Grants
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant with Maintenance Temozolomide and Placebo for the Treatment of Newly D
Clinical TrialPrincipal Investigator · Awarded by Novocure GmbH · 2025 - 2030A Phase 1b/2, multicenter study of vorasidenib in combination with temozolomide (TMZ) in participants with IDH1- or IDH2-mutant glioma
Clinical TrialPrincipal Investigator · Awarded by Servier Bio-Innovation, LLC · 2025 - 2030A Phase 1, Safety Lead-in and Randomized, Open-label, Perioperative Study of Vorasidenib in Combination with Pembrolizumab in Subjects with Recurrent or Progressive Enhancing IDH-1 Mutant Astrocytomas)
Clinical TrialPrincipal Investigator · Awarded by Servier Pharmaceuticals · 2023 - 2029Circle of Service Foundation Challenge Grant
Institutional SupportCo Investigator · Awarded by Circle of Service Foundation · 2023 - 2028"ViCToRy: Vorasidenib in Combination with Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas
Clinical TrialPrincipal Investigator · Awarded by Servier Pharmaceuticals · 2024 - 2028An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients with Relapsed or Refractory Primary Central Nervous System Lymphoma
Clinical TrialPrincipal Investigator · Awarded by Curis, Inc. · 2024 - 2028An open-label phase II study to investigate the efficacy and safety of tirabrutinib in patients with Primary Central Nervous System Lymphoma (PCNSL)
Clinical TrialPrincipal Investigator · Awarded by ONO PHARMACEUTICAL CO., LTD. · 2023 - 2028A randomized controlled phase 2 study of the ketogenic diet for patients with newly diagnosed glioblastoma in combination with standard-of-care treatment
ResearchPrincipal Investigator · Awarded by Cedars Sinai Medical Center · 2023 - 2028A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma
Clinical TrialPrincipal Investigator · Awarded by Nerviano Medical Sciences S.r.l. (NMS S.r.l.) part of NMS Group SpA · 2024 - 2027A phase 2 double-blind, RandomizEd, prospective, placebo controlled STudy of NanO2 TM combined with Radiation and temozolomide in patients with newly-diagnosed glioblastoma multiformE: RESTORE
Clinical TrialPrincipal Investigator · Awarded by NuvOx Pharma, LLC · 2023 - 2027Clinical and Radiographic Outcomes for Patients with IDH Mutant Gliomas using Ivosidenib
ResearchPrincipal Investigator · Awarded by Servier Pharmaceuticals · 2024 - 2027A Phase 1-2 dose-escalation and expansion study of ST101 in patients with advanced unresectable and metastatic solid tumors
Clinical TrialPrincipal Investigator · Awarded by Sapience Therapeutics Inc. · 2022 - 2027Improved monitoring of 2-Hydroxyglutarate to stage response of combined Vorasidenib and Tumor Specific Peptide Vaccine therapies in recurrent IDH1 mutant lower grade glioma
ResearchCo-Principal Investigator · Awarded by National Cancer Institute · 2022 - 2026A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects wiht Residual or Recurrent Grade 2 Glioma wiht an IDH1 or IDH2 Mutation (INDIGO)
Clinical TrialPrincipal Investigator · Awarded by Servier Pharmaceuticals · 2020 - 2026GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (GCAR-7213)
Clinical TrialPrincipal Investigator · Awarded by Global Coalition · 2021 - 2025GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM (GCAR-7213)
Clinical TrialPrincipal Investigator · Awarded by Global Coalition for Adaptive Research · 2023 - 2025A Phase 1, Multicenter, Randomized, Controlled, Open-label, Perioperative Study of AG-120 and AG-881 in Subjects with Recurrent, Non-enhancing, IDH1 Mutant, Low-grade Glioma. (AG120-881-C-001)
Clinical TrialPrincipal Investigator · Awarded by Agios Pharmaceuticals, Inc. · 2018 - 2025ADI-PEG 20 (Pegargiminase) Treatment Arm
Clinical TrialPrincipal Investigator · Awarded by Global Coalition for Adaptive Research · 2024 - 2025A phase 1, multicenter, open-label, dose-escalation and expansion, safety, pharmacokinetic, pharmacodynamic, and clinical activity study of orally administered AG-881 in patients with advanced solid tumor, including gliomas, with an IDh1 and IDH2 mut
Clinical TrialPrincipal Investigator · Awarded by Agios Pharmaceuticals, Inc. · 2015 - 2024Survivorship study of cancer patients who received cranial radiation therapy focus on health-related quality of life and cognition (SPiRiT)
Clinical TrialPrincipal Investigator · Awarded by Varian Medical Systems, Inc. · 2021 - 2024BMX-001 AS A THERAPEUTIC AGENT FOR TREATMENT OF MULTIPLE BRAIN METASTASES
Clinical TrialCo Investigator · Awarded by BioMimetix JV LLC · 2018 - 2023Namzaric® for Irradiated Primary Brain Tumor Survivors: A Phase III Randomized Placebo-Controlled 24-Week Clinical Trial
Clinical TrialPrincipal Investigator · Awarded by Allergan, Inc. · 2021 - 2023Functional Capacity and Physical Function in Glioblastoma Patients Treated with or without Tumor-Treating Fields
ResearchPrincipal Investigator · Awarded by Novocure · 2018 - 2022A Phase 1/2 Trial for Patients with Newly Diagnosed High Grade Glioma Treated with Concurrent Radiation Therapy, Temozolomide, and BMX-001
ResearchPrincipal Investigator · Awarded by BioMimetix JV LLC · 2020 - 2022A randomized phase 3 Open label study of Nivolumab vs Temozolomide each in combination with radiation therapy in newly diagnosed adult subjects with unmethylated MGMT glioblastoma (CA209-498)
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2016 - 2022Efficacy of dendritic cell vaccines targeting CMV antigens in glioblastoma
ResearchInvestigator · Awarded by University of Florida · 2017 - 2021Tissue Factor as a Key Determinant of IDH1 Mutant versus IDH1 Wild-type Glioma Thrombosis and Malignancy
ResearchPrincipal Investigator · Awarded by Northwestern University · 2020 - 2021Quantitative Staging and Therapeutic Response in IDH-1 Mutated Glioblastomas
ResearchCo Investigator · Awarded by National Institutes of Health · 2017 - 2021A Randomized Phase IIB Open Label Study of Nivolumab in combination with Ipilimumab versus Bevacizumab in Adult Subjects with Recurrent Glioblastoma (GBM)
Clinical TrialPrincipal Investigator · Awarded by The Bristol-Myers/Sanofi Pharmaceuticals, Inc. Partnership · 2014 - 2021A Study for Management of Ocular Side Effects in Subjects with EGFR-Amplified Glioblastoma receiving Depatuxizumab Mafodotin
Clinical TrialPrincipal Investigator · Awarded by AbbVie Inc. · 2018 - 2020A randomized phase 2 single blind study of temozolomide plus radiation therapy combined with nivolumab or placebo in newly diagnosed adult subjects with MGMT-methylated glioblastoma (BMS CA209-548)
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2016 - 2020Ph 1/2 Trial for Patients with Newly Diagnosed High Grade Glioma Treated with Concurrent Radiation Therapy, Temozolomide, and BMX-001
Clinical TrialPrincipal Investigator · Awarded by BioMimetix JV LLC · 2015 - 2020Characterizing the non-medical resource utilization of caregivers of individuals with GBM
ResearchPrincipal Investigator · Awarded by University of Utah · 2018 - 2019Observational study: Assessing the impace of glioblastoma multiforme on the quality of life of patients
ResearchPrincipal Investigator · Awarded by AbbVie Inc. · 2017 - 2019A Phase II Study of Pembrolizumab (MK3475) with and without Bevacizumab
Clinical TrialPrincipal Investigator · Awarded by Dana-Farber Cancer Institute · 2015 - 2019Assessment of Nonenhancing Tumor Volume Change Before and After Chemoradiation Treatment: Low Grade Glioma
ResearchPrincipal Investigator · Awarded by Brigham and Women's Hospital · 2016 - 2018External Relationships
- AnHeart
- Nuvation Bio Inc
- Ono pharma USA, Inc.
- Pathos
- Rigel Pharmaceuticals, Inc
- Sapience
- Servier
- telix pharmaceuticals
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.